TY - JOUR
T1 - The impact of drug metabolism gene polymorphisms on therapeutic response and survival in diffuse large B-cell lymphoma patients
AU - Pál, Ildikó
AU - Illés, Árpád
AU - Gergely, Lajos
AU - Pál, Tibor
AU - Radnay, Zita
AU - Szekanecz, Zoltán
AU - Zilahi, Erika
AU - Váróczy, László
N1 - Publisher Copyright:
© 2018, Israel Medical Association. All rights reserved.
PY - 2018/4
Y1 - 2018/4
N2 - Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of all non-Hodgkin lymphomas (NHL) and 80% of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. Objectives: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. Methods: The study was comprised of 51 patients (32 men, 19 women). The average age was 53.1 years. DLBCL was diagnosed between 2011 and 2016 and the average follow-up time was 3.78 years. These patients received 1–8 cycles (an average of 6.2 cycles) of rituximab, cyclophosphamide, doxorubicin, vincristin, prednisolon (R-CHOP) immunochemotherapy. Real-time polymerase chain reaction was used to determine the genetic polymorphisms of CYP2E1, GSTP1, NAT1, and NAT2 genes. Results: Our results showed that the polymorphisms of CYP2E1, GSTP1, and NAT1 genes did not influence the prognosis of DLBCL patients significantly. In terms of the NAT2 gene, GG homozygous patients showed slightly better therapeutic response and survival results compared to those bearing an A allele; however, the differences were not statistically significant. Conclusions: Our results could not confirm that genetic polymorphism in metabolic pathways has any predictive role in DLBCL.
AB - Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of all non-Hodgkin lymphomas (NHL) and 80% of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. Objectives: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. Methods: The study was comprised of 51 patients (32 men, 19 women). The average age was 53.1 years. DLBCL was diagnosed between 2011 and 2016 and the average follow-up time was 3.78 years. These patients received 1–8 cycles (an average of 6.2 cycles) of rituximab, cyclophosphamide, doxorubicin, vincristin, prednisolon (R-CHOP) immunochemotherapy. Real-time polymerase chain reaction was used to determine the genetic polymorphisms of CYP2E1, GSTP1, NAT1, and NAT2 genes. Results: Our results showed that the polymorphisms of CYP2E1, GSTP1, and NAT1 genes did not influence the prognosis of DLBCL patients significantly. In terms of the NAT2 gene, GG homozygous patients showed slightly better therapeutic response and survival results compared to those bearing an A allele; however, the differences were not statistically significant. Conclusions: Our results could not confirm that genetic polymorphism in metabolic pathways has any predictive role in DLBCL.
KW - Diffuse large B-cell lymphoma (DLBCL)
KW - Event-free survival
KW - Genetic polymorphism
KW - Non-Hodgkin lymphoma (NHL)
KW - Therapeutic efficacy
UR - http://www.scopus.com/inward/record.url?scp=85045523914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045523914&partnerID=8YFLogxK
M3 - Article
C2 - 29629728
AN - SCOPUS:85045523914
SN - 1565-1088
VL - 20
SP - 217
EP - 221
JO - Acta medica Orientalia
JF - Acta medica Orientalia
IS - 4
ER -